SCHEMBL3307271

SCHEMBL3307271

COC(=O)c1cc2cccnc2nc1O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.49
HTT P42858 1/20 0.49
KDM4E B2RXH2 7/20 0.48
ALDH1A1 P00352 3/20 0.46
HPGD P15428 2/20 0.46
MAP2K1 Q02750 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
TDP1 Q9NUW8 1/20 0.44
EGLN1 Q9GZT9 1/20 0.41
SLC40A1 Q9NP59 1/20 0.41
LMNA P02545 2/20 0.41
TSHR P16473 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
MAPT P10636 1/20 0.41
PKM P14618 1/20 0.41
POLB P06746 2/20 0.39
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31345639 1.00 ALOX15 (0.49) ALOX15HTTKDM4EALDH1A1HPGD
SCHEMBL28558680 0.85 ALOX15 (0.49) ALOX15HTTKDM4EALDH1A1HPGD
SCHEMBL1680890 0.84 MAOA (0.47) HTTKDM4EALDH1A1HPGDTSHR
SCHEMBL253152 0.84 KDM4E (0.48) ALOX15HTTKDM4EALDH1A1HPGD
SCHEMBL15128363 0.84 ALOX15 (0.48) ALOX15HTTKDM4EALDH1A1HPGD
SCHEMBL352470 0.81 KDM4E (0.53) ALOX15KDM4EALDH1A1NPSR1TDP1
SCHEMBL973413 0.80 ALOX15 (0.45) ALOX15HTTKDM4EALDH1A1HPGD
SCHEMBL70306 0.76 ALOX15 (0.65) ALOX15HTTKDM4EALDH1A1HPGD
SCHEMBL30905588 0.76 ALOX15 (0.65) ALOX15HTTKDM4EALDH1A1HPGD
SCHEMBL16234345 0.76 KDM4E (0.51) ALOX15HTTKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119585247-A Bicyclic heterocyclic amide inhibitors of nav1.8 for the treatment of pain 赛特温治疗公司 2025-03-07 CN disclosed
EP-4514789-A1 <SUP2/>? <SUB2/>?V?BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA1.8 FOR THE TREATMENT OF PAIN SiteOne Therapeutics, Inc. (US) 2025-03-05 EP disclosed
WO-2023211990-A1 BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA V1.8 FOR THE TREATMENT OF PAIN SITEONE THERAPEUTICS, INC. (US) 2023-11-02 WO disclosed
WO-2023211990-A1 BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA V1.8 FOR THE TREATMENT OF PAIN SITEONE THERAPEUTICS, INC. (US) 2023-11-02 WO disclosed
EP-2086982-B1 HCV NS3 PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2018-08-29 EP disclosed
US-9738661-B2 HCV NS3 protease inhibitors MERCK SHARP & DOHME CORP. (US) 2017-08-22 US disclosed
US-9738661-B2 HCV NS3 protease inhibitors MERCK SHARP & DOHME CORP. (US) 2017-08-22 US disclosed
US-9738661-B2 HCV NS3 protease inhibitors MERCK SHARP & DOHME CORP. (US) 2017-08-22 US disclosed
US-20150266897-A1 HCV NS3 Protease Inhibitors MSD ITALIA S.R.L. (IT) 2015-09-24 US disclosed
US-20150266897-A1 HCV NS3 Protease Inhibitors MSD ITALIA S.R.L. (IT) 2015-09-24 US disclosed
US-20150266897-A1 HCV NS3 Protease Inhibitors MSD ITALIA S.R.L. (IT) 2015-09-24 US disclosed
US-20100099695-A1 HCV NS3 Protease Inhibitors MSD ITALIA S.R.L. (IT) 2010-04-22 US disclosed
US-20100099695-A1 HCV NS3 Protease Inhibitors MSD ITALIA S.R.L. (IT) 2010-04-22 US disclosed
US-20100099695-A1 HCV NS3 Protease Inhibitors MSD ITALIA S.R.L. (IT) 2010-04-22 US disclosed
EP-2086982-A1 HCV NS3 PROTEASE INHIBITORS Merck & Co., Inc. (US) 2009-08-12 EP disclosed
WO-2008057209-A1 HCV NS3 PROTEASE INHIBITORS MERCK & CO., INC. (US) 2008-05-15 WO disclosed
WO-2008057209-A1 HCV NS3 PROTEASE INHIBITORS MERCK & CO., INC. (US) 2008-05-15 WO disclosed
US-4957640-A Corrosion prevention with compositions prepared from organic fatty amines and nitrogen-containing aromatic heterocyclic compounds THE DOW CHEMICAL COMPANY (US) 1990-09-18 US disclosed
US-4765839-A PAVING THE DOW CHEMICAL COMPANY (US) 1988-08-23 US disclosed
US-4761473-A CORROSION RESISTANCE OF OIL OR GAS WELLS THE DOW CHEMICAL COMPANY (US) 1988-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099695-A1 HCV NS3 Protease Inhibitors HAVCR2, GTF3C3, CTSC ALOX15 1183/4885HTT 3331/4885KDM4E 2747/4885
US-20150266897-A1 HCV NS3 Protease Inhibitors HAVCR2, GTF3C3, CTSC ALOX15 1183/4885HTT 3331/4885KDM4E 2747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.